Evidence map›Paper›PMID 41113425›Full record

ReviewSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Advances in Surgical Treatment Following Conversion Therapy for Pancreatic Cancer].

Lingwei Meng, Yongbin Li, Bing Peng

Abstract readReviewEnglish Abstract
In one paragraph

Review in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lingwei Meng( 610041) Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0000-0002-3374-1716
Yongbin Li( 610041) Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Bing Peng( 610041) Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0009-0000-2307-1301

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is characterized by an insidious onset, high invasiveness, and poor response to treatment. Radical resection remains the only potentially curative approach currently available. However, approximately 80% of patients are already in the locally advanced or metastatic stage at initial diagnosis and have missed the opportunity for radical surgery. In recent years, with the development of novel drugs and updates to chemotherapy regimens, significant progress has been made in improving the efficacy of conversion therapy. Conversion therapy aims to transform initially unresectable tumors, such as locally advanced or metastatic pancreatic cancer, into a resectable state through systemic therapies (including chemotherapy, targeted therapy, immunotherapy, etc.) combined with localized treatments (such as radiotherapy, interventional therapy, etc.). This approach reduces tumor volume and eliminates micrometastases, thereby improving surgical resection rates and patient survival outcomes. However, considerable controversy remains regarding surgical treatment after conversion therapy for pancreatic cancer. This article provides an overview of conversion therapy regimens and treatment cycles, methods for evaluating therapeutic efficacy post-conversion therapy, the resection rates, and treatment outcomes of surgery following conversion therapy. The key technical points of post-conversion therapy surgery, including R0 resection, venous management, arterial resection and reconstruction, and the management of periarterial divestment, are highlighted. The learning curve for arterial resection and reconstruction is also discussed. Additionally, the potential applications of minimally invasive techniques (such as laparoscopy and robotics) are highlighted. The integration of biomarkers, imaging, and artificial intelligence holds promise for optimizing individualized decision-making. Multidisciplinary collaboration, the comprehensive competence of the surgical team, and the mastery and refinement of surgical skills are also critical factors that influence resectability and therapeutic outcomes after conversion therapy.

Indexed as

PancreatectomyPancreatic NeoplasmsCombined Modality TherapyHumansArterial resectionConversion surgeryConversion therapyPancreatic cancerPeriarterial divestmentReview

Identifiers

PMID41113425
PMCPMC12531000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.